Sub-retinal implant
Colin Kerr
Published: Wednesday, November 1, 2017
Pixium Vision has announced that its next-generation miniaturised wireless sub-retinal implant, PRIMA, has received authorisation from the French regulatory agency, Agence nationale de sécurité du médicament et des produits de santé (ANSM), to start a feasibility clinical study in patients with advanced dry age-related macular degeneration (dry-AMD).
Khalid Ishaque, Chief Executive Officer of Pixium Vision, a company developing bionic vision systems to enable patients who have lost their sight to lead more independent lives, commented: “PRIMA enters an exciting phase of its development, with a first patient expected to be implanted before year end.”
www.pixium-vision.com
Tags: sub-retinal implant
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.